Scheduled for 7:00 a.m. EST on November 19, 2015
Presentations to begin at 7:15 a.m. EST
FORT WASHINGTON, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY.
Presentations will begin at 7:15 a.m. EST and leading academic experts are scheduled to speak.
For additional information and registration, please email email@example.com or call 443-213-0506.
A live audio webcast of the event will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. The Company's lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied for atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.
CONTACT: INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 firstname.lastname@example.org Westwicke Partners John Woolford (443) 213-0506 email@example.com MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 firstname.lastname@example.org